Huntington's Disease Market Size-By Treatment - Regional Outlook, Competitive Strategies and Segment Forecast to 2032

Global Huntington's Disease Market Overview:

According to SPER Market Research, the Global Huntington's Disease Market is estimated to reach USD 2.65 billion by 2032 with a CAGR of 19.83%.

The global market for Huntington's disease is expanding as a result of significant R&D expenditures for the creation of novel products, research partnerships, and the high prevalence of HD in western nations. An uncommon hereditary neurological disorder that affects multiple generations, is Huntington's disease. People in adult age are affected, which limits their ability to work, take care of their families, and finally finish everyday duties. The numbers vary between regions, which can be attributed to differences in case ascertainment and diagnostic standards. Also, the incidence varies between regions, which can be attributed to differences in case ascertainment and diagnostic standards. As a result, larger repeats may be more common than anticipated in the general population. While Europe, North America, and Australia have greater prevalence's, the Asian population has continuously had a lower prevalence. The key players are concentrating on the research and development of HD symptomatic treatments. An investigational medication called SRX246 is being created by Azevan Pharmaceuticals to treat the neuropsychiatric signs and symptoms of Huntington's disease. The medicine SRX246 functions by obstructing the brain's vasopressin 1a (V1a) receptor. The primary vasopressin receptor in the nervous system is the V1a receptor. By blocking the V1a receptor and preventing vasopressin from binding to the receptor, SRX246 causes the agitated and violent behaviour that is typical of people with Huntington's disease. The medications that are now approved, however, only treat the symptoms of the condition and offer palliative care. While drugs might lessen a patient's symptom intensity, they are frequently linked to side effects such as somnolence, gait problems, dysphagia, and apathy that can seriously impair a patient's quality of life. It is crucial to assess how these patients' Health-related Quality of Life (HRQOL) is affected given the lack of treatment for the illness. Early to mid-stage HD patients require integrated multidisciplinary healthcare treatments, such as counselling and assessments of cognitive function. As a result of various medicines' inability to show effectiveness or their high levels of toxicity, drug development for HD has encountered considerable challenges. Patients with early manifest and prodromal HD did not meet the pre-specified co-primary outcomes in Vaccinex Inc.'s phase II study of pepinemab. The Huntington's disease Cognitive Assessment Battery family comprising two cognitive tests and the Clinical Global Impression of Change (CGIC) did not reach statistical significance in the SIGNAL study's early manifestation sample. Due to the availability of medicine and patent protection, the symptomatic treatment category had the highest revenue share in the last year. The entrance of SAGE-718 and Cellavita-HD is expected to make disease-modifying treatments the market sector with the fastest growth over the next years. Instead of targeting the mutant protein, businesses are now concentrating on the development of drugs that can be injected into the brain to prevent the creation of mutant HTT protein. Early-stage pharmaceuticals with innovative targets include Cellavita HD (stem cell treatment) by Cellavita and Azidus Brazil, mHTT ZFP by Sangamo Therapeutics, Inc., and AMT-130 by UniQure (gene therapy). The market for the treatment of Huntington's disease is now dominated by the symptomatic treatment sector, which also had the highest revenue share. The availability of symptom management treatments and the patent protection afforded to these medications are to blame for this rise. When it comes to first-line treatment for chorea brought on by Huntington's disease, Xenazine and Austedo are recommended.

Impact of COVID-19 on the Global Huntington's Disease Market:

The worldwide COVID-19, however, caused a slowdown in the therapy market for Huntington's disease. Antidepressants, antipsychotics, and anticonvulsants were among the off-label medications sold by online pharmacies during the epidemic to treat HD symptoms. Clinical experiments during the COVID-19 pandemic were halted because to the government shutdown.

Scope of the report:

• Market size available for the years: 2019-2032

• Base year considered: 2021

• Forecast Period: 2022-2032

• Segments Covered: By Treatment

• Regions Covered: Asia-Pacific, Europe, Middle East and Africa, North America, Latin America

• Companies Covered: Annexon Biosciences, Bausch Health Companies Inc., Dr. Reddy's Laboratories Ltd, Eli Lilly and Company, H. Lundbeck A/S, Hetero, Hikma Pharmaceuticals PLC, Lupin, Medesis pharma SA, Mitochon Pharmaceuticals, Neurocrine bioscience Inc., Novartis, PTC Therapeutics, Inc., SOM Biotech, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., UniQure, Vaccinex, Inc.

Global Huntington's Disease Market Segmentation:

• By Treatment: Based on the Treatment, Global Huntington's Disease Market is segmented as; Symptomatic treatment, Disease-modifying therapies.

• By Region: Due to improved reimbursement infrastructure and the significant financial burden of HD in the United States and Canada, North America, which accounted for the greatest revenue share in previous year, is anticipated to dominate the market throughout the forecast period.